

**LISTING OF THE CLAIMS**

1 -16. **(Cancelled)**

17. **(Withdrawn)** The epitope of claim 1, wherein the polypeptide is encoded by a nucleic acid.

18. **(Previously presented)** A composition comprising an isolated epitope, the isolated epitope comprising a component selected from the group consisting of:

- (i) a polypeptide epitope having the sequence as disclosed in TABLE 1B;
- (ii) an epitope cluster comprising the polypeptide of (i);
- (iii) a polypeptide sequence variant of (i) or (ii), wherein said sequence variant of (i) or (ii) comprises a sequence variation of a conservative amino acid substitution; and
- (iv) a polypeptide having functional similarity to any of (i) through (iii), wherein said functional similarity to any of (i) through (iii) comprises induction of a CTL response cross-reactive with any of (i) through (iii);

a second isolated epitope having the sequence selected from the group consisting of SEQ ID NO: 108, SEQ ID NO: 312, SEQ ID NO: 354, SEQ ID NO: 364, SEQ ID NO: 430 and SEQ ID NO: 572;

and a pharmaceutically acceptable adjuvant, carrier, diluent, or excipient.

19. **(Previously presented)** The composition of claim 18, where the adjuvant is a polynucleotide.

20. **(Previously presented)** The composition of claim 19 wherein the polynucleotide comprises a CpG dinucleotide.

21. **(Previously presented)** The composition of claim 18, wherein the adjuvant is encoded by a polynucleotide.

22. **(Previously presented)** The composition of claim 18 wherein the adjuvant is a cytokine.

23. **(Previously presented)** The composition of claim 23 wherein the cytokine is GM-CSF.

24. **(Previously presented)** The composition of claim 18 further comprising a professional antigen-presenting cell (pAPC).

25. **(Previously presented)** The composition of claim 18, further comprising a second epitope.

26. **(Previously presented)** The composition of claim 25, wherein the second epitope is a polypeptide.

27. **(Withdrawn)** The composition of claim 25, wherein the second epitope is a nucleic acid.

28. **(Previously presented)** The composition of claim 25, wherein the second epitope is a housekeeping epitope.

29. **(Previously presented)** The composition of claim 25, wherein the second epitope is an immune epitope.

30. **(Withdrawn)** A recombinant construct comprising the nucleic acid of Claim 1.

31. **(Withdrawn)** The construct of claim 30, further comprising a plasmid, a viral vector, a bacterial vector, or an artificial chromosome.

32. **(Withdrawn)** The construct of claim 30, further comprising a sequence encoding at least one feature selected from the group consisting of a second epitope, an IRES, an ISS, an NIS, and ubiquitin.

33. **(Previously presented)** A composition comprising:

at least one component selected from the group consisting of a polypeptide epitope having the sequence as disclosed in TABLE 1B; a composition comprising a polypeptide having the sequence as disclosed in TABLE 1B; a composition comprising an isolated T cell expressing a T cell receptor specific for an MHC-peptide complex, the complex comprising a polypeptide having the sequence as disclosed in TABLE 1B; an isolated T cell expressing a T cell receptor specific for an MHC-peptide complex, the complex comprising a polypeptide having the sequence as disclosed in TABLE 1B;

an isolated epitope having the sequence selected from the group consisting of SEQ ID NO: 108, SEQ ID NO: 312, SEQ ID NO: 354, SEQ ID NO: 364, SEQ ID NO: 430 and SEQ ID NO: 572; and

a pharmaceutically acceptable adjuvant, carrier, diluent, or excipient.

34. **(Withdrawn)** A method of treating an animal, comprising:

administering to an animal the composition of claim 33.

35. **(Withdrawn)** The method of claim 34, wherein the administering step comprises a mode of delivery selected from the group consisting of transdermal, intranodal, perinodal, oral, intravenous, intradermal, intramuscular, intraperitoneal, mucosal, aerosol inhalation, and instillation.

36. **(Withdrawn)** The method of claim 34, further comprising a step of assaying to determine a characteristic indicative of a state of a target cell or target cells.

37. **(Withdrawn)** The method of claim 36, comprising a first assaying step and a second assaying step, wherein the first assaying step precedes the administering step, and wherein the second assaying step follows the administering step.

38. **(Withdrawn)** The method of claim 37, further comprising a step of comparing the characteristic determined in the first assaying step with the characteristic determined in the second assaying step to obtain a result.

39. **(Withdrawn)** The method of claim 38, wherein the result is selected from the group consisting of: evidence of an immune response, a diminution in number of target cells, a loss of mass or size of a tumor comprising target cells, a decrease in number or concentration of an intracellular parasite infecting target cells.

40. **(Previously presented)** A method of making a vaccine, comprising:  
combining at least one component selected from the group consisting of a polypeptide epitope having the sequence as disclosed in TABLE 1B; a composition comprising a polypeptide having the sequence as disclosed in TABLE 1B; a composition comprising an isolated T cell expressing a T cell receptor specific for an MHC-peptide complex, the complex comprising a polypeptide having the sequence as disclosed in TABLE 1B; a composition comprising a host cell expressing a recombinant construct, the construct encoding a protein molecule comprising the binding domain of a T cell receptor specific for an MHC-peptide complex; an isolated T cell expressing a T cell receptor specific for an MHC-peptide complex, the complex comprising a polypeptide having the sequence as disclosed in TABLE 1B; and a host cell expressing a recombinant construct,

the construct encoding a protein molecule comprising the binding domain of a T cell receptor specific for an MHC-peptide complex; and

an isolated epitope having the sequence selected from the group consisting of SEQ ID NO: 108, SEQ ID NO: 312, SEQ ID NO: 354, SEQ ID NO: 364, SEQ ID NO: 430 and SEQ ID NO: 572;

with a pharmaceutically acceptable adjuvant, carrier, diluent, or excipient.